Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study.
Shoemaker K, Soboleva K, Branche A, Shankaran S, Theodore DA, Bari M, Ezeh V, Green J, Kelly E, Lan D, Olsson U, Saminathan S, Shankar NK, Villegas B, Villafana T, Falsey AR, Sobieszczyk ME.
Shoemaker K, et al. Among authors: olsson u.
Vaccines (Basel). 2024 Aug 3;12(8):883. doi: 10.3390/vaccines12080883.
Vaccines (Basel). 2024.
PMID: 39204009
Free PMC article.